Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

1.10USD
2 Dec 2016
Change (% chg)

$0.03 (+2.80%)
Prev Close
$1.07
Open
$1.08
Day's High
$1.10
Day's Low
$1.05
Volume
47,418
Avg. Vol
108,214
52-wk High
$3.00
52-wk Low
$0.51

CPRX.OQ

Chart for CPRX.OQ

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 2.17
Market Cap(Mil.): $101.10
Shares Outstanding(Mil.): 82.87
Dividend: --
Yield (%): --

Financials

  CPRX.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.24 -- --
ROI: -37.39 -1.09 14.95
ROE: -38.10 -2.39 16.29

BRIEF-Catalyst Pharmaceuticals announces Q3 2016 financial results

* Catalyst Pharmaceuticals-continues to believe currently available resources will be sufficient to complete development of Firdapse

Nov 09 2016

BRIEF-Catalyst Pharmaceuticals gets FDA special protocol assessment for phase 3 trial of lems treatment

* Says intends to conduct its second phase 3 trial (designated as lms-003) at two clinical trial sites

Oct 31 2016

BRIEF-Catalyst Pharmaceuticals' board entered into amendment no. 1 to rights agreement

* On September 19, 2016, board unanimously approved, and entered into amendment no. 1 to rights agreement - SEC filing

Sep 20 2016

BRIEF-Catalyst Pharmaceuticals announces FDA orphan drug designation of Firdapse

* Catalyst Pharmaceuticals announces FDA orphan drug designation of Firdapse for the treatment of Myasthenia Gravis

Sep 02 2016

BRIEF-Catalyst Pharmaceuticals announce Q2 2016 financial results and provides product development update

* Catalyst Pharmaceuticals announces second quarter 2016 financial results and provides product development update

Aug 09 2016

BRIEF-Catalyst Pharma finalizes late-stage trial design with FDA for Firdapse

* Catalyst Pharmaceuticals announces agreement with FDA on confirmatory phase 3 study protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome

Jun 13 2016

Earnings vs. Estimates